COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00160654
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : November 15, 2013
Information provided by:
UCB Pharma

Brief Summary:

Community based study assessing safety and efficacy of levetiracetam in partial onset seizures.

The optimal dose in daily clinical practice will be used.

Condition or disease Intervention/treatment Phase
Epilepsy, Partial Drug: Levetiracetam Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 345 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: A Phase IV, Open-label, Multi-center, Community-based Trial Studying the Safety and Efficacy of Keppra™ as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy.
Study Start Date : November 2003
Actual Primary Completion Date : May 2006
Actual Study Completion Date : May 2006

Primary Outcome Measures :
  1. To assess safety of levetiracetam

Secondary Outcome Measures :
  1. To evaluate efficacy of levetiracetam in community based practice.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Subjects with epilepsy experiencing partial seizures, whether or not secondarily generalized.
  • Subjects must present between 3 and 42 partial seizures over the three months prior to protocol Visit 1.
  • Use of one (1), but no more than two (2) concomitant marketed AEDs at the time of trial entry.

Exclusion Criteria:

  • Subjects on vigabatrin, whose visual field has not been assessed as per recommendation of the manufacturer, i.e. every 6 months.
  • Presence of known pseudoseizures within the last year.
  • Presence of progressive cerebral disease, any other progressively degenerative neurological disease, or any cerebral tumors.
  • Uncountable seizures (clusters) or history of convulsive status epilepticus within the last five years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00160654

Layout table for location information
Hong Kong
Hong Kong, Hong Kong
Kwun Tong (Kowloon), Hong Kong
Kuala Llumpur, Malaysia
Penang, Malaysia
Manila, Philippines
Quezon, Philippines
Singapore, Singapore
Changua, Taiwan
Hualien, Taiwan
Kaohsiung County, Taiwan
Kaohsiung, Taiwan
Taichung, Taiwan
Tainan, Taiwan
Taipei, Taiwan
Taoyuan County, Taiwan
Bangkok, Thailand
Chiangmai, Thailand
Khon Kaen, Thailand
Sponsors and Collaborators
UCB Pharma
Layout table for investigator information
Study Director: UCB Clinical Trial Call Center UCB Pharma
Additional Information:
Publications of Results:
Layout table for additonal information Identifier: NCT00160654    
Other Study ID Numbers: N01036
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: November 15, 2013
Last Verified: July 2010
Keywords provided by UCB Pharma:
Partial Onset Seizures
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsies, Partial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Nootropic Agents